Comparative Pharmacology
Head-to-head clinical analysis: CUTIVATE versus DEXONE 0 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUTIVATE versus DEXONE 0 5.
CUTIVATE vs DEXONE 0.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to inhibit inflammatory mediators, vasoconstriction, and immunosuppression.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor (GR) and modulating gene expression through transactivation and transrepression. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, suppresses cytokine production (IL-1, IL-2, IL-6, TNF-alpha), and decreases immune cell migration and activation.
Apply a thin layer to affected skin areas once or twice daily. Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
0.5 mg orally once daily, with gradual taper to lowest effective dose
None Documented
None Documented
2-4 hours (terminal elimination half-life); short half-life supports twice-daily dosing for maintenance of clinical effect.
3.0-4.5 hours; prolonged in hepatic impairment (up to 6-8 hours) or concurrent CYP3A4 inhibitors
Primarily hepatic metabolism; metabolites are excreted renally and fecally. Unchanged drug is negligible in urine. Route: renal (~60% as metabolites), fecal (~40% as metabolites).
Renal: 70-80% (mostly as 6β-hydroxydexamethasone); biliary/fecal: 10-15%
Category C
Category C
Corticosteroid
Corticosteroid